WORK Medical Technology Group LTD (WOK)
WORK Medical Technology Group LTD makes medical devices and consumables in China and sells them around the world. The company is based in Hangzhou City in Zhejiang Province. Its ticker symbol is WOK on NASDAQ. The company was founded in 2002 and has been making and exporting medical supplies for more than twenty years.
What WORK does is straightforward: it manufactures simple, high-volume medical supplies that hospitals, clinics, and medical institutions need to run. Masks, breathing tubes, airways, tourniquets for bleeding control. The stuff that gets used once and thrown away. None of these products are high-tech on their own. What matters is making them reliably, affordably, and in volume.
The product line
WORK makes twenty-one products today. The core products are things like non-inflatable laryngeal masks—used to manage airways during anesthesia—and endotracheal tubes for patients who need ventilation. It makes disposable breathing circuits that deliver oxygen or anesthetic gases. It makes medical-grade face masks. It makes tourniquets and artery compression devices for trauma and bleeding control. It makes endotracheal tube holders to keep tubes positioned correctly.
Some of these are customized versions. WORK will design a mask with specific features to meet a hospital’s needs. Some are standard products that any hospital in the world would recognize.
The company has FDA registrations for seventeen of its products, meaning they can be legally sold in the United States. The rest are sold elsewhere.
How it makes money
WORK sells to hospitals and medical institutions directly. It exports to about thirty countries across Asia, Africa, Europe, North America, South America, and Oceania. It is not a direct-to-consumer business. Everything goes through medical institutions and their purchasing departments.
Revenue is mostly from consumables—products that get used, depleted, and reordered. Once a hospital adopts WORK’s mask or tube, it orders them regularly. The economics are margin-based, not volume-based at the start. Medical consumables typically have high gross margins because the products are inexpensive and the barrier to entry is regulatory (FDA approval, manufacturing certifications) rather than pure manufacturing cost.
In fiscal 2025, WORK reported revenue of 9.85 million dollars. In the previous year, revenue was 11.51 million dollars. The decline of about fourteen percent indicates that either volumes fell, prices fell, or some customers switched suppliers.
Manufacturing in China
The company’s location in China is a strategic advantage and a strategic risk. Advantage: wages and manufacturing overhead in China are lower than in the United States or Europe, so WORK can make these products profitably at prices hospitals are willing to pay. Over twenty years, the company has built manufacturing expertise and supply chains.
Risk: geopolitics. U.S.-China trade tensions, tariffs, and export controls could affect WORK’s ability to sell into America or get components. China is also where a lot of medical device manufacturing happens globally, so WORK is competing against many other Chinese makers with the same cost advantages.
Expanding into diagnostics
Recently WORK moved into a more complex product category. Through a subsidiary called Hunan Saitumofei, the company developed an AI-Automated Human Blood Cell Morphology Analyzer. This is a Class II medical device—a machine that looks at blood samples and uses artificial intelligence to identify and classify cells. It is more complicated to build, more expensive to buy, and more technically sophisticated than a mask or breathing tube.
The company obtained manufacturing approval for this analyzer, indicating it passed Chinese regulatory review. This is a diversification away from simple consumables into higher-value diagnostic equipment.
What to watch
Anyone researching WORK should look at its 10-K filing (SEC CIK 0001929783) to understand which hospitals or regions account for most revenue, whether the company is winning or losing share in any market, and whether the new diagnostic device is generating meaningful sales or is still in early adoption.
Key questions: Is the revenue decline a temporary dip or a trend? Are hospitals switching to competitors, or are they just delaying purchases? Is the new blood cell analyzer actually getting adopted by labs, or is it still mostly on the company’s books as development-stage?
The basic business—selling simple consumables to hospitals—is stable and well-understood. The growth story depends on whether WORK can successfully scale the diagnostic device and whether it can grow sales outside China in established markets where other suppliers already have relationships.